IMMUNOPOTENTIATION BY A NEW ANTITUMOR POLYSACCHARIDE, DMG, A DEGRADED D-MANNO-D-GLUCAN FROM MICROELLOBOSPORIA-GRISEA CULTURE FLUID

Abstract

The immunopharmacological behavior of DMG [degraded D-manno-D-glucan], an antitumor polysaccharide, was studied in mice. DMG administered i.p. or s.c. stimulated peritoneal macrophages to produce high levels of interleukin 1 activity, which can amplify successive immune responses. DMG dose-dependently and schedule-dependently increased the cellular immune response against allogeneic tumor cells and the humoral immune response to sheep erythrocytes. DMG also enhanced nonspecific antitumor effector functions, such as natural killer activity of spleen and peritoneal cells, and the cytostatic activity of peritoneal macrophages. Peritoneal macrophages activated by i.p. or s.c. injection of DMG exhibited high cytostatic activity, especially after exposure in vitro to lymphokine supernatants containing macrophage activation factor. Granulocyte/macrophage colony-stimulating activity in the serum increased 2-10 h after DMG administration. DMG potentiated antigen-specific immunological functions and nonspecific functions of host defense systems against cancer both qualitatively and quantitatively.